PBA2, a novel inhibitor of the β-catenin/CBP pathway, eradicates chronic myeloid leukemia including BCR-ABL T315I mutation

Abstract Background BCR-ABL is a constitutively active tyrosine kinase that stimulates multiple downstream signaling pathways to promote the survival and proliferation of chronic myeloid leukemia (CML) cells. The clinical application of specific BCR-ABL tyrosine kinase inhibitors (TKIs) has led to s...

Full description

Bibliographic Details

Published in:	Molecular Cancer
Main Authors:	Ke Yang, Kai Fu, Hong Zhang, Xiaokun Wang, Kenneth K.W. To, Caibo Yang, Fang Wang, Zhe-Sheng Chen, Liwu Fu
Format:	Article
Language:	English
Published:	BMC 2024-09-01
Subjects:	CBP p300 Cell differentiation Cell senescence Chronic myeloid leukemia T315I mutation
Online Access:	https://doi.org/10.1186/s12943-024-02129-1